The seed capital will help UAB-founded TriAltus Bioscience commercialise its protein purification materials, which are already being used by research clients in the US, Brazil and EU.

TriAltus Bioscience, a US-based protein purification technology spinout of University of Alabama at Birmingham (UAB), has raised $1.6m in a seed round featuring unnamed angel investors. Founded in 2017, TriAltus Bioscience is commercialising protein purification materials that utilise a technique called CL-4 affinity purification to quickly isolate proteins at a higher purity than alternative methods. The technology is designed for scientific research applications such as the production of therapeutic proteins. In addition to the purification technology, TriAltus also plans to directly market a select number of finished proteins to researchers. The round will help TriAltus demonstrate proof-of-concept and launch CL-7 affinity products as it looks to add business to early custom from research clients in the US, Brazil and the EU.  The capital is expected to sustain operations for 18 months. TriAltus extends research led by chief scientific officer Dmitry Vassylyev, professor of biochemistry and molecular genetics at UAB’s School of Medicine whose lab will continue development of the technology under a sponsored research agreement with the spinout. The company’s intellectual property was licensed through the UAB Bill L. Harbert Institute for Innovation and Entrepreneurship, which retains equity interest in TriAltus and is entitled to royalty and milestone fees.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?